On-target, off-tumor toxicity refers to the adverse effects that occur when a therapeutic agent, designed to target specific cancer cells, also affects healthy cells expressing the same target. This phenomenon underscores the challenge in developing treatments that are both effective against cancer and safe for normal tissues.